NCT01597388 2026-02-24
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
AstraZeneca
Phase 1 Completed
Clinical Trials
5 trialsNCT03334617 2025-10-27
HUDSON
AstraZeneca
Phase 2 Active not recruiting
NCT03366103 2023-10-17
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT03205046 2021-01-06
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Acerta Pharma BV
Phase 1/2 Terminated
NCT01026402 2016-02-11
Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014
AstraZeneca
Phase 1 Completed